Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.
In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody
Anwendungsbeschreibung:
Applications: ELISA,neutralization,functional assays such as bioanalytical PK and ADA assays,and those assays for studying biological pathways. ResearchArea: Cancer immunology. Shipping: Ice Bag
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
